摘要
心肌缺血再灌注损伤是导致心血管疾病心肌损伤的最重要原因，常见于冠心病和心脏手术围手术期，发生率和死亡率高，其机制涉及氧化应激、炎性反应和细胞凋亡等。目前的治疗措施包括药物治疗和物理治疗，但效果不佳。氢气作为一种小分子无毒还原性气体，在细胞缺血再灌注损伤中有明显保护作用，是未来治疗缺血再灌注损伤的重要方向，本文就氢气治疗心肌缺血再灌注损伤的作用机制及其未来应用临床的初步展望进行综述。
Abstract
Myocardial ischemia-reperfusion injury (MIRI) is one of the key causes of myocardial injury, secondary to cardiovascular diseases, which is mostly present in coronary heart disease and during the perioperative period of cardiac surgery. MIRI elicits oxidative stress, inflammatory activity, and cell apoptosis, with a high incidence and mortality rate. The current treatments for MIRI include medicines and physical therapy, but with unsatisfactory effects. As a small molecule non-toxic reducing gas, hydrogen has a clear protective effect against cell ischemia-reperfusion, and has therefore become a promising treatment for MIRI. This paper reviews the mechanism of hydrogen for the treatment of MIRI and the preliminary prospect of its clinical application in the future.
基金项目
中央引导地方科技发展资金项目(2021ZY0026)
内蒙古自治区教育厅“高校青年科技英才”项目(NJYT22021)
内蒙古自治区医疗卫生科技计划项目(202201310)
万方数据